Doxi-Hem capsules 500mg, 90pcs

Composition

1 capsule contains the Active ingredient: Calcium dobesilate (in the form of Calcium dobesilate monohydrate 521.51 mg) – 500.00 mgsupport substances: Corn starch-25.164 mg Magnesium stearate-8.326 mg; Capsule No. 0: Body: Titanium dioxide E 171-0.8640 mg, Iron oxide yellow dye E 172-0.1440 mg; Cap: Dye iron oxide black E 172 — 0,1920 mg, dye Indigo Carmine E 132 — 0,1728 mg, titanium dioxide E 171 — 0,4800 mg, dye iron oxide yellow E 172 — 0,5760 mg,96 mg gelatin to the

Pharmacological action of

Pharmacodynamics . another, reduces increased permeability of blood vessels, increases the resistance of the capillary walls, improves microcirculation and drainage function of lymphatic vessels, moderately reduces platelet aggregation and blood viscosity, increases the elasticity of the membrane of red blood cells. The action is associated to a certain extent with an increase in the activity of plasma kinins. Pharmacokinetics Rapidly absorbed in the gastrointestinal tract. The maximum concentration in blood plasma is reached 6 hours after oral use. Binding to plasma proteins is 20-25%. Practically does not penetrate the blood-brain barrier. It is excreted by the kidneys (about 50%) and through the intestines (about 50%) mainly unchanged for 24 hours,10% – in the form of metabolites. The elimination half-life is 5 hours. In very small amounts (0.4 mcg/ml after taking 1.5 g of the drug) is excreted in breast milk.

Indications

• Vascular lesions with increased fragility and capillary permeability (diabetic retinopathy and nephropathy) and other microangiopathies associated with various cardiovascular and metabolic diseases.

• Venous insufficiency of various degrees of severity and its consequences (pre-varicose condition with the phenomena of tissue edema, pain, paresthesia, congestive dermatosis; superficial phlebitis, varicose veins, trophic ulcers).

Use during pregnancy and lactation

Adequate and strictly controlled studies on the safety of use in pregnant and lactating women have not been conducted. The use of the drug is contraindicated in the first trimester of pregnancy. In the second and third trimesters of pregnancy, the drug is prescribed only for vital indications if the expected effect of use exceeds the possible risk to the fetus. When prescribing during lactation, it is necessary to decide whether to stop breastfeeding.

Recommendations for use

Inside, without chewing, while eating. Assign 500 mg 3 times a day for 2-3 weeks, then the dose is reduced to 500 mg 1 time a day. In the treatment of retinopathy and microangiopathy,500 mg is prescribed 3 times a day for 4-6 months, then the daily dose is reduced to 500 mg 1 time a day. The course of treatment is from 3-4 weeks to several months, depending on the therapeutic effect.

Contraindications

Hypersensitivity to calcium dobesilate or any component of the drug, peptic ulcer of the stomach and duodenum 12 (in the acute stage), bleeding from the gastrointestinal tract, kidney and liver diseases, hemorrhages caused by anticoagulants; pregnancy (I trimester), children (up to 13 years).

Side effects

Classification of adverse reactions by frequency of development: often-1-10%, infrequently-0.1-1%, rarely-0.01-0.1%, very rarely, including individual cases — Disorders of the gastrointestinal tract. Rare: nausea, diarrhea, vomiting. Skin and subcutaneous tissue disorders. Rare: allergic reactions (pruritus, rash). General disorders. Rare: fever, chills. Musculoskeletal and connective tissue disorders. Rare: arthralgia. Disorders of the blood and lymphatic system. In some cases: agranulocytosis. The reaction is reversible and disappears after discontinuation of therapy.

Interaction

Cases of drug interaction of calcium dobesilate have not yet been identified.

How to take, course of use and dosage

Inside, without chewing, while eating. Assign 500 mg 3 times a day for 2-3 weeks, then the dose is reduced to 500 mg 1 time a day. In the treatment of retinopathy and microangiopathy,500 mg is prescribed 3 times a day for 4-6 months, then the daily dose is reduced to 500 mg 1 time a day. The course of treatment is from 3-4 weeks to several months, depending on the therapeutic effect.

Overdose

No cases of overdose were reported.

Special instructions

The drug can be prescribed prophylactically. If symptoms of agranulocytosis appear (fever, headache, chills, weakness, pain when swallowing, inflammation of the oral mucosa), you should immediately consult a doctor and conduct a clinical blood test. Calcium dobesilate may affect the results of laboratory tests to determine creatinine levels. Influence on the ability to drive vehicles and work with mechanicsthe drug does not adversely affect the ability to drive vehicles and work with mechanisms.

Form of production

500 mg capsules. 10 capsules in a PVC/AL blister. 3 blisters with instructions for use in a cardboard pack.

Storage conditions

At a temperature not exceeding 25°C in consumer packaging. Keep out of reach of children.

Shelf life

5 years

Active ingredient

Calcium Dobesilate

Conditions of release from pharmacies

By prescription

Dosage form

Capsules

Description

Children as prescribed by a doctor, Adults as prescribed by a doctor, Pregnant women in the second and third trimester as prescribed by a doctor, Children over 13 years of age

Indications

Trophic Ulcers, Diabetic Nephropathy, Diabetic Retinopathy